Angiotension receptor blockers reduce the risk of dementia

Journal of Hypertension

Volumn 32, Issue 4, 2014, Pages 938-947

  Chiu, Wei Che ^a,b,c   Ho, Wen Chao ^d   Lin, Meng Hung ^d   Lee, Hsiu Hao ^a,e   Yeh, Yu Chi ^b,f   Wang, Jung Der ^a,g   Chen, Pau Chung ^a,h  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI CITY HOSPITAL   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^h NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Alzheimer's disease; Angiotension receptor blocker; Antihypertensive therapy; Dementia

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MEMANTINE; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ALZHEIMER DISEASE; AMBULATORY CARE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DRUG EFFECT; DRUG USE; DSM-IV; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ICD-9; INCIDENCE; INCOME; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTIINFARCT DEMENTIA; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REIMBURSEMENT; RISK REDUCTION; TAIWAN; TREATMENT DURATION; URBANIZATION; VERY ELDERLY; FACTUAL DATABASE; PATHOPHYSIOLOGY; RISK FACTOR; DOSE RESPONSE; LOW RISK PATIENT;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DEMENTIA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TAIWAN;

EID: 84896317851     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000086     Document Type: Article

References (45)

1. Urosevic N, Martins RN. Infection and Alzheimer's disease: The APOE epsilon4 connection and lipid metabolism. J Alzheimers Dis 2008; 13:421-435
2. Daviglus ML, Plassman BL, Pirzada A, Bell CC, Bowen PE, Burke JR, et al. Risk factors and preventive interventions for Alzheimer's disease: State of the science. Arch Neurol 2011; 68:1185-1190
3. Beeri MS, Rapp M, Silverman JM, Schmeidler J, Grossman HT, Fallon JT, et al. Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology 2006; 66:1399-1404
4. Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, Kunik ME. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother 2009; 7:250-261
5. Johnson ML, Parikh N, Kunik ME, Schulz PE, Patel JG, Chen H, et al. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimers Dement 2012; 8:437-444
6. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: New evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162:2046-2052
7. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163:1069-1075
8. Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: Results from the systolic hypertension in the elderly program. Arch Intern Med 1994; 154:2154-2160
9. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The study on cognition and prognosis in the elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886
10. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): A double-blind, placebo controlled trial. Lancet Neurol 2008; 7:683-689
11. Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-Levi AC, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: A network meta-analysis. J Hypertens 2013; 31:1073-1082
12. Skoog I, Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res 2006; 28:605-611
13. Kehoe PG. Angiotensins and Alzheimer's disease: A bench to bedside overview. Alzheimers Res Ther 2009; 1:3
14. Igase M, Kohara K, Miki T. The association between hypertension and dementia in the elderly. Int J Hypertens 2012; 2012:320648
15. Fogari R, Mugellini A, Zoppi A, Derosa G, Pasotti C, Fogari E, Preti P. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens 2003; 17:781-785
16. Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B, et al. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005; 18:1052-1059
17. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. BMJ 2010; 340:b5465
18. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of antihypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 2011; 26:699-708
19. Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen TJ, Chiang CE. Long-term use of angiotensin II receptor blockers and risk of cancer: A population-based cohort analysis. Int J Cardiol 2012; 337:536-542
20. Horiuchi M, Mogi M. Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage. Br J Pharmacol 2011; 163:1122-1130
21. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117:3393-3402
22. Mogi M, Li JM, Tsukuda K, Iwanami J, Min LJ, Sakata A, et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun 2008; 375:446-449
23. Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision (ICD-9). Atlanta, GA: CDC; 1979. http:// www.cdc.gov/nchs/icd/icd9.htm. [Accessed 10 January 2011]
24. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011; 20:236-242
25. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012; 30:623-630
26. Chi NF, Chien LN, Ku HL, Hu CJ, Chiou HY. Alzheimer disease and risk of stroke: A population-based cohort study. Neurology 2013; 80:705-711
27. National Health Research Institutes. National Health Insurance Research Database. http://www.nhri.org.tw/nhird/date-01.html#edn1. [Accessed 1 January 2011]
28. Sun Y, Lai MS, Lu CJ, Chen RC. How long can patients with mild or moderate Alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: A national population-based study. Eur J Neurol 2008; 15:278-283
29. Lönnroos E, Kyyrönen P, Bell JS, van Der Cammen TJ, Hartikainen S. Risk of death among persons with Alzheimer's disease: A national register-based nested case-control study. J Alzheimers Dis 2013; 33:157-164
30. WHO Collaborating Centre for drug statistics methodology. Guidelines for ATC classification and DDD assignment, 2013. Oslo, 2012. http:// www.whocc.no/filearchive/publications/1-2013guidelines.pdf 31. Staessen JA, Thijs L, Richart T, Odili AN, Birkenhäger WH. Placebocontrolled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension 2011; 57:e6-e7
31. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289:2560-2572
32. Ismail H, Mitchell R, McFarlane SI, Makaryus AN. Pleiotropic effects of inhibitors of the RAAS in the diabetic population: Above and beyond blood pressure lowering. Curr Diab Rep 2010; 10:32-36
33. Chou CC, Lin WS, Kao TW, Chang YW, Chen WL. Adherence to available clinical practice guidelines for initiation of antihypertensive medication in patients with or without diabetes mellitus and other comorbidities in Taiwan. J Clin Pharmacol 2012; 52:576-585
34. Ozacmak VH, Sayan H, Cetin A, Akyildiz-Igdem A. AT1 receptor blocker candesartan-induced attenuation of brain injury of rats subjected to chronic cerebral hypoperfusion. Neurochem Res 2007; 32:1314-1321
35. Ferrington L, Miners JS, Palmer LE, Bond SM, Povey JE, Kelly PA, et al. Angiotensin II-inhibiting drugs have no effect on intraneuronal A( or oligomeric A( levels in a triple transgenic mouse model of Alzheimer's disease. Am J Transl Res 2011; 3:197-208
36. Fournier A, Oprisiu-Fournier R, Serot JM, Godefroy O, Achard JM, Faure S, et al. Prevention of dementia by antihypertensive drugs: How AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother 2009; 9:1413-1431
37. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163:1069-1075
38. Poon IO. Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy 2008; 28:366-375
39. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007; 6:373-378
40. Sharma B, Singh N. Experimental hypertension induced vascular dementia: Pharmacological, biochemical and behavioral recuperation by angiotensin receptor blocker and acetylcholinesterase inhibitor. Pharmacol Biochem Behav 2012; 102:101-108
41. Hajjar I, Rodgers K. Do angiotensin receptor blockers prevent Alzheimer's disease? Curr Opin Cardiol 2013; 28:417-425
42. Fuh JL, Wang SJ. Dementia in Taiwan: Past, present, and future. Acta Neurol Taiwan 2008; 17:153-161
43. Chien IC, Lin YC, Chou YJ, Lin CH, Bih SH, Lee CH, Chou P. Treated prevalence and incidence of dementia among National Health Insurance enrollees in Taiwan, 1996-2003. J Geriatr Psychiatry Neurol 2008; 21:142-148
44. Taylor DH Jr, Fillenbaum GG, Ezell ME. The accuracy of medicare claims data in identifying Alzheimer's disease. J Clin Epidemiol 2002; 55:929-937
45. Fillit H, Geldmacher DS, Welter RT, Maslow K, Fraser M. Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias. J Am Geriatr Soc 2002; 50:1871-1878